Q: What need is Clusterone addressing? A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome....
Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI? A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the...
Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve? A: We are focused on physical resilience, or the dynamic ability to maintain or recover function following a stressor....
Q: What need is LabCorp addressing? A: The timeless issues LabCorp continues to address are those related to delivering world-class diagnostics solutions, bringing innovative medicines to patients faster and using technology to improve the delivery of healthcare....
Q: What need is LifeOmic addressing? A: Precision Medicine requires the aggregation of huge data sets, including data representing individual patients from the level of their genomes all the way up through various levels of their phenomes....
Q: GeneCentric employs Drug Response Biomarkers developed via the Cancer Subtyping Platform (CSP). What makes your approach of biomarker development unique? A: By applying CSPTM technology, GeneCentric is developing universal drug response biomarkers to enable more effective and efficient drug development informed by high resolution,...
Q: What need is Precision BioSciences addressing? A: Precision’s ARCUS genome editing technology is a proprietary, non-CRIPSR platform that has applications across cell therapy, gene therapy, and agriculture. We are able to edit everything from plants to primates, so prioritizing projects is an imporant part...
Q: Why is preemptive pharmacogenetics testing important in the context of personalized medicine? A: We estimated that pharmacogenetic test results can impact the use of nearly 100 drugs, accounting for up to 18% of current prescriptions. Therefore, having pharmacogenetic test results already “in hand” at the...
Q: What need is Datavant addressing? A: While the volume of health data grows precipitously year over year, our ability to make use of that data is not keeping pace. There are many aspects to the inherent challenges and opportunities of this data explosion...
In the age of big DNA data, it is important to remember that accumulating large amounts of data is not enough. Equally important is keeping the DNA data that participants provide as diverse as possible to allow us to generate answers to questions about how...
